Version 1
: Received: 16 May 2023 / Approved: 17 May 2023 / Online: 17 May 2023 (05:13:35 CEST)
How to cite:
Ishikawa, T.; Sato, R.; Jimbo, R.; Kobayashi, Y.; Sato, T.; Iwanaga, A.; Sano, T.; Yokoyama, J.; Honma, T. Balloon-Occluded Transarterial Chemoembolization for Hepatocellular Carcinoma in the Modern Drug Therapy Era. Preprints2023, 2023051192. https://doi.org/10.20944/preprints202305.1192.v1
Ishikawa, T.; Sato, R.; Jimbo, R.; Kobayashi, Y.; Sato, T.; Iwanaga, A.; Sano, T.; Yokoyama, J.; Honma, T. Balloon-Occluded Transarterial Chemoembolization for Hepatocellular Carcinoma in the Modern Drug Therapy Era. Preprints 2023, 2023051192. https://doi.org/10.20944/preprints202305.1192.v1
Ishikawa, T.; Sato, R.; Jimbo, R.; Kobayashi, Y.; Sato, T.; Iwanaga, A.; Sano, T.; Yokoyama, J.; Honma, T. Balloon-Occluded Transarterial Chemoembolization for Hepatocellular Carcinoma in the Modern Drug Therapy Era. Preprints2023, 2023051192. https://doi.org/10.20944/preprints202305.1192.v1
APA Style
Ishikawa, T., Sato, R., Jimbo, R., Kobayashi, Y., Sato, T., Iwanaga, A., Sano, T., Yokoyama, J., & Honma, T. (2023). Balloon-Occluded Transarterial Chemoembolization for Hepatocellular Carcinoma in the Modern Drug Therapy Era. Preprints. https://doi.org/10.20944/preprints202305.1192.v1
Chicago/Turabian Style
Ishikawa, T., Junji Yokoyama and Terasu Honma. 2023 "Balloon-Occluded Transarterial Chemoembolization for Hepatocellular Carcinoma in the Modern Drug Therapy Era" Preprints. https://doi.org/10.20944/preprints202305.1192.v1
Abstract
The indications for TACE in the treatment of hepatocellular carcinoma have become more stringent with the development of systemic pharmacotherapy. Radical TACE is expected to be used only in situations such as for tumors with small volume which fulfill the “up-to-7”. Furthermore, a combination of molecular-targeted agents is expected to maximize the efficacy of TACE. In the intermediate stage, TACE and drug therapy play complementary roles, and it is important to select a treatment strategy that considers tumor status and hepatic reserve. However, no studies have investigated the various types of TACE in the treatment of such patients. Currently, TACE in Japan is broadly classified into conventional TACE, balloon occluded TACE (B-TACE), and drug-eluting beads TACE (DEB-TACE). This article outlines the evolution of B-TACE for hepatocellular carcinoma in the drug therapy era.
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
